Victory Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Victory Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-20,706	Closed	-$78K	–	3693
2020 Q1	$78K	Buy	+20,706	New	+$89.2K	﹤0.01%	2615
2019 Q4	–	Sell	-11,902	Closed	-$60K	–	3669
2019 Q3	$60K	Buy	+11,902	New	+$59.4K	﹤0.01%	2609

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Victory Capital Management's PGNX Position: Q2 2020 in Review

Victory Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 20,706 shares — an estimated $78K sold.

Victory Capital Management first reported a position in PGNX in Q3 2019 and held it in 2 quarters. The position peaked at $78K in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Victory Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Victory Capital Management sold 20,706 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $78K.
Victory Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2019 and held it in 2 quarters.
Victory Capital Management's Progenics Pharmaceuticals Inc position peaked at $78K in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.